Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
CLYM is expected to report earnings to fall 41.94% to -18 cents per share on August 19
Q2'25
Est.
$-0.18
Q1'25
Missed
by $0.16
The last earnings report on May 14 showed earnings per share of -31 cents, missing the estimate of -15 cents. With 130.81K shares outstanding, the current market capitalization sits at 114.88M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. CLYM showed earnings on May 14, 2025. You can read more about the earnings report here.